Like many rare disease charities, the Pulmonary Hypertension Association (PHA) was formed in 1991 by four women sitting around a kitchen table in Florida, hoping for a cure. Yet the PHA is probably the only patient advocacy group that actually preserved its original kitchen table and chairs — and made…
News
An antibody that recognizes and blocks the activity of osteoprotegerin, a protein involved in the development of pulmonary arterial hypertension (PAH), was able to stop and even reverse disease progression in animal and cell models of PAH, a study reports. The study, “A therapeutic antibody…
Use of Bellerophon Therapeutics’s INOpulse device led to clinically meaningful improvements in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to initial data from an ongoing clinical study. PH-ILD is associated with constriction or narrowing of pulmonary arteries, which supply the lungs with…
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…
The vasodilator INOpulse increased physical activity and helped maintain higher levels of exercise in people at risk of pulmonary hypertension (PH) associated with pulmonary fibrosis (PH-PF), preliminary results from a Phase 2 trial show. The results were presented in two posters at the Pulmonary Fibrosis Foundation Summit 2019,…
Infants with mild or severe forms of persistent pulmonary hypertension of the newborn, who were discharged from hospital, were significantly more likely to be readmitted or die within their first year of life, with the primary cause being congenital abnormalities, a study has…
Iconovo has signed a Letter of Understanding with CrystecPharma to collaborate on the design and development of new dry powder inhaler (DPI) products to be used for precise drug delivery into the lungs of patients with a wide variety of lung diseases, including pulmonary hypertension. Many…
Fifteen out of 18 patients (83%) enrolled in the Phase 2 HELP study testing levosimendan achieved the predefined response required in the open-label phase of the study, Tenax Therapeutics announced. The investigational therapy is a potential treatment for pulmonary hypertension (PH) and heart failure with preserved ejection fraction (PH-HFpEF). The response…
November is Pulmonary Hypertension Awareness Month, and this year, the Pulmonary Hypertension Association (PHA) is highlighting risk factors and symptoms associated with the disease. PHA’s social media campaign, titled “PHaces of Hope,” is based on stories from pulmonary hypertension (PH) patients and their caregivers, as well…
Having pulmonary hypertension (PH) does not affect the benefits of lung volume reduction surgery for people with emphysema, who experience improved lung function and better quality of life, a new study suggests. The study, published in The Annals of Thoracic Surgery, was titled “Pulmonary Hypertension: A…
INOpulse can improve physical activity in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and helps them to maintain a higher level of activity, data presented at the 2019 meeting of the American College of Chest Physicians suggest. INOpulse is a therapy that uses inhaled nitric oxide (iNO),…
Oral treatment with rodatristat ethyl is safe and reduced the levels of serotonin — a hormone whose high levels may promote the tightening of pulmonary artery muscle cells — in healthy volunteers, a study has shown. The results were presented in a poster, titled “Once Daily Oral Dosing…
